Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide therapeutic approaches if antigens specific for pancreatic cancer cells can be identified. Here we characterize SAS1B (ovastacin, ASTL, astacin-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Knapp, Kiley A., Pires, Eusebio S., Adair, Sara J., Mandal, Arabinda, Mills, Anne M., Olson, Walter C., Slingluff, Craig L., Parsons, J. Thomas, Bauer, Todd W., Bullock, Timothy N., Herr, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5823626/
https://ncbi.nlm.nih.gov/pubmed/29507667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados